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Background: Randomized clinical trials demonstrated that car-
diac resynchronization therapy (CRT) improves survival in pa-
tients with congestive heart failure. The data of survival in
patients treated in naturalized practice is sparse and no data is
available from India.
Methods: The clinical and device data of patients who had un-
dergone CRT implantation at least 5 years before were analyzed.
Results: The follow up data is available from 61 patients out of
total 78 patients who have had CRT atleast 5 years before. The
mean follow up period was 7.5 (range 5 e 12) years.There were 44
(72%)males. The mean age was 58 ±13 (range 29 e 67) years. None
of the patients had AICD indication for secondary prevention of
sudden cardiac death and all of them were in NYHA class III.
Coronary angiography was normal at the time of implant in 61%
(N¼ 37). Thirteen patients (21%) have died.Nine (70%) patients had
ischemic heart disease. On the basis of the clinical records and
device data, the cause of death was considered sudden in six (46%)
patients. All of the patients who have died had documented AF
and renal dysfunction.
Conclusion: Atleast one in five patients with CRT die over a follow
up period of 5 years and nearly half of the deaths are sudden.
Renal dysfunction and atrial fibrillation are themarkers of highest
risk.
Valvular Heart Disease (RHD)
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Objective: To study the prevalence of Rheumatic heart disease
using echo Doppler in School Children of Trivandrum.
Methods: A total of 2060 students aged 5 e 15 years from five
Government (1023) and two private schools (aided) (1037) were
screened. Schools were randomly selected. All children and
parents in each school were informed regarding the study,
consent forms sent home through children. Children with
informed written consent from parents were included in study.
Subjects were interviewed using a proforma, a detailed clinical
examination and echo Doppler study using Philips (HD-11)
machine in schools. World heart federation 2012 criteria were
used to identify RHD children. Data analysed using SPSS
software.
Results: Of all 2060 children, 64.8% were males and 35.2% were
females and mean age was 12.6 ± 2.1years. Clinical examination
detected murmur in 184 subjects, of which 32 (17.4%) subjects
detected to have a heart disease by echocardiographic evaluation.
Out of 45 subjects with apical systolic murmur, 5(11.1%) subjects
had RHD by echocardiography, clinical prevalence being 2.4/1000
(95%CI 1.1-4.2). Clinical prevalence of RHD (by h/o of rheumatic
fever and clinical apical systolic murmur was found in one child)
to be 0.49 /1000(95% CI 0-1.4).
All subjects underwent echo Doppler evaluation. Echo Doppler
evaluation diagnosed RHD in 12 children, of which 6 children had
definite RHD, 6 had borderline RHD by WHF criteria, giving a
prevalence of 5.83 /1000 (95%CI 2.5-9.1) school children. Definite
RHD byWHF criteria was 2.9 /1000 school children. Anteriormitral
valve thickness>3mm and mitral regurgitation waspresent in all.
Aortic regurgitation was seen in five school children by echo.
Mitral regurgitation was grade 1 in 140 children and grade 2 in 6
children. None had severe MR by echo or hemodynamically sig-
nificant MR. Of 146 children with mitral regurgitation, 24 children
had apical systolic murmur. Anterior mitral leaflet prolapse sug-
gestive of rheumatic etiology with pathological MR seen in 3
children. None of the subjects had commissural fusion and mitral
stenosis. Two children had history of acute rheumatic fever on
secondary prophylaxis, of which one had history of rheumatic
chorea.
Conclusion: It is the first and largest school survey study in Kerala
for Rheumatic heart disease using echo Doppler till date. Echo
prevalence of RHD was several folds higher compared to clinical
prevalence. Our study suggest that RHD prevalence by echo
Doppler is less in Kerala(5.83/1000), due to its better socioeco-
nomic living standards, better health indices, availability of
prompt medical care and less overcrowding(4.4±1comparedwith
6.4± 2.3, RHEUMATICstudy, Delhi) and higher literacy rates among
females.
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Background: Beta-blockers are frequently used in patients with
mitral stenosis to control the heart rate and alleviate exercise-
related symptoms. The objective of our study was to examine
whether ivabradine was superior to atenolol for achieving higher
exercise capacity in patients withmoderatemitral stenosis (MS) in
sinus rhythm. We also evaluated their effects on left ventricular
myocardial performance index (MPI).
Methods and Results: Eighty-two patients with moderate mitral
stenosis in sinus rhythm were randomized to receive ivabradine
(n¼42) 5 mg twice daily or atenolol (n¼40) 50 mg daily for 6
weeks. Trans-thoracic echocardiography and treadmill test were
performed at baseline and after completion of 6 weeks of treat-
ment. Mean total exercise duration in seconds markedly
improved in both study groups at 6 weeks (298.57±99.05sec vs.
349.12±103.53sec; p¼0.0001 in ivabradine group, 290.90± 92.42 sec
vs. 339.90± 99.84sec; p¼0.0001in atenolol group). On head to head
comparison, there was no significant change in improvement of
exercise time between ivabradine and atenolol group (p¼0.847).
Left ventricular myocardial performance index did not show any
significant change from baseline and at 6 weeks in both drug
groups (49.8 ± 8% vs. 48.3± 7% in ivabradine group, 52.9± 10% vs.
50.9± 10% in atenolol group; p¼0.602).
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